FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Pfaffle Antony   2. Issuer Name and Ticker or Trading Symbol CorMedix Inc. [CRMD] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Scientific Officer (Last) (First) (Middle) C/O CORMEDIX INC., 1430 US HIGHWAY 206, SUITE 200 3. Date of Earliest Transaction (Month/Day/Year) 02/07/2017 (Street) BEDMINSTER, NJ 07921 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 02/07/2017   M   10,000 A $ 0.68 10,000 D   Common Stock 02/07/2017   S(1)   10,000 D $ 2 0 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Stock Option (right to buy)

$ 0.68

02/07/2017

M(1)

10,000

(2)

12/05/2022

Common Stock, $0.001 par value per share

10,000

$ 0

70,000

D

stock Option (right to buy)

$ 3.125

(3)

03/30/2020

Common Stock, $0.001 par value per share

20,000

20,000

D

Stock Option (right to buy)

$ 2.1

(4)

01/14/2021

Common Stock, $0.001 par value per share

30,000

30,000

D

Stock Option (right to buy)

$ 0.9

(5)

03/22/2023

Common Stock, $0.001 par value per share

210,000

210,000

D

Stock Option (right to buy)

$ 2.02

(6)

01/09/2024

default

30,000

30,000

D

Stock Option (right to buy)

$ 2.02

(7)

01/09/2024

Common Stock, $0.001 par value per share

100,000

100,000

D

Stock Option (right to buy)

$ 2.27

(8)

04/01/2024

Common Stock, $0.001 par value per share

100,000

100,000

D

Stock Option (right to buy)

$ 5

(9)

02/24/2025

Common Stock, $0.001 par value per share

75,000

75,000

D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Pfaffle Antony C/O CORMEDIX INC. 1430 US HIGHWAY 206, SUITE 200 BEDMINSTER, NJ 07921			Chief Scientific Officer

Signatures

/s/ Alexander M. Donaldson, with a Power of Attorney for Antony E. Pfaffle, M.D.		02/08/2017
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	This exercise and sale was effected pursuant to a Rule 10b5-1 trading plan executed by the reporting person on September 19, 2016.
(2)	These options vested as follows: fifty percent (50%) on the date of issuance of the CE mark certification, which occurred on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.
(3)	These options vested as follows: 1/3 on March 30, 2010; an additional 1/3 on March 30, 2011; and the remaining 1/3 on March 30, 2012.
(4)	These options vested on January 14, 2012.
(5)	These options vest based on performance milestones running through December 31, 2014.
(6)	The options vest in full on the first anniversary of the date of grant.
(7)	The options vested 100% on January 10, 2014.
(8)	The options vested 100% on April 2, 2014.
(9)	These options were granted on February 24, 2015, and vested immediately.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.